[1]Schleusener JT, Tazelaar HD, Jung SH, et.al. Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma. Cancer, 1996, 77(7): 1284-1291.
[2]Berendsen HH, de Leij L, Poppema S, et al. Clinical characterization of non-small-cell lung cancer tumors showing neuroendocrine differentiation features. J Clin Oncol, 1989, 7(11): 1614-1620.
[3]李维华. 肺神经内分泌癌的分类、病理诊断及临床病理联系. 临床与实验病理学杂志, 1998,14(2):180-182.
[4]郭春梅,张羲娥,李亭,等. 肺神经内分泌癌的临床和MDCT表现. 川北医学院学报,2011,26(2):163-166.
[5]Insabato L, Del Basso De Caro M, Caramanna E, et al. Pathology of neuroendocrine tumours. Front Biosci(Landmark Ed), 2009,14:4712-4718.
[6]Travis WD, Garg K, Franklin WA, et al. Bronchioloalveolar carcinoma and lung adenocarcinoma:the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. J Thorac Oncol,2006,1(9 Suppl):S13-S19.
[7]李海,邓志勇,徐松,等. 免疫组化技术在肺神经内分泌肿瘤病理诊断中的应用. 西南军医, 2010,12(6):1100-1101.
[8]李维华. 肺鳞状细胞癌伴神经内分泌分化的超微结构及免疫组织化学观察.中华病理学杂志, 1991, 20(2): 116-118.
[9]余少平,熊永炎,田素芳. 非小细胞肺癌多药耐药及神经内分泌分化的相关性研究. 中华结核和呼吸杂志, 2003, 26(3):165-168. |
京公安网备11010202008787号
Total visitors: Visitors of today: Now online:
This work is licensed under Creative Commons Attribution 3.0 License.
